Agilent Technologies (A) Scheduled to Post Quarterly Earnings on Tuesday

Agilent Technologies (NYSE:A – Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 23rd. Analysts expect the company to announce earnings of $1.27 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Agilent Technologies (NYSE:A – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.06. The business had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.70 billion. Agilent Technologies had a return on equity of 30.35% and a net margin of 19.09%. The business’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business posted $1.21 EPS. On average, analysts expect Agilent Technologies to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Agilent Technologies Trading Up 0.4 %

Shares of NYSE A opened at $127.99 on Tuesday. The company has a market cap of $37.85 billion, a price-to-earnings ratio of 28.89, a price-to-earnings-growth ratio of 1.96 and a beta of 1.03. Agilent Technologies has a 12-month low of $112.52 and a 12-month high of $160.26. The company has a current ratio of 2.11, a quick ratio of 1.53 and a debt-to-equity ratio of 0.49. The stock’s 50 day simple moving average is $135.35 and its 200 day simple moving average is $144.65.

Agilent Technologies Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 26th. Investors of record on Tuesday, April 4th were issued a $0.225 dividend. This represents a $0.90 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend was Monday, April 3rd. Agilent Technologies’s dividend payout ratio (DPR) is 20.32%.

Institutional Trading of Agilent Technologies

Institutional investors have recently bought and sold shares of the company. Money Concepts Capital Corp acquired a new stake in Agilent Technologies during the fourth quarter valued at $26,000. Ancora Advisors LLC bought a new position in Agilent Technologies during the fourth quarter valued at about $34,000. Resurgent Financial Advisors LLC bought a new position in Agilent Technologies during the fourth quarter valued at about $57,000. Altshuler Shaham Ltd raised its holdings in Agilent Technologies by 94.6% during the fourth quarter. Altshuler Shaham Ltd now owns 395 shares of the medical research company’s stock valued at $59,000 after buying an additional 192 shares in the last quarter. Finally, Penserra Capital Management LLC bought a new position in Agilent Technologies during the first quarter valued at about $60,000. Institutional investors and hedge funds own 85.51% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Credit Suisse Group raised their target price on Agilent Technologies from $165.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. StockNews.com cut Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 29th. Barclays initiated coverage on Agilent Technologies in a research report on Thursday, May 11th. They issued an “equal weight” rating and a $140.00 target price on the stock. Finally, Robert W. Baird lifted their price target on Agilent Technologies from $170.00 to $174.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $161.64.

About Agilent Technologies

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.